Where Can I Get Tirzepatide Cheap in 2026? The Complete Pricing Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide from licensed telehealth platforms costs $179 to $499 monthly, compared to $940 to $1,350 for brand-name Mounjaro or Zepbound without insurance
• The Lilly savings card reduces brand-name copays to $25 monthly for eligible commercial insurance patients, but excludes Medicare, Medicaid, and uninsured patients
• Costco consistently offers the lowest cash price for brand-name tirzepatide among major retail pharmacies, typically $50 to $150 less than CVS or Walgreens
• Patient assistance programs from Eli Lilly provide free brand-name tirzepatide for qualifying low-income patients earning under 400% of federal poverty level

Direct answer (40-60 words)

The cheapest legitimate tirzepatide sources in 2026 are compounded versions from licensed telehealth platforms ($179 to $499 monthly), Eli Lilly's patient assistance program (free for qualifying low-income patients), or brand-name Mounjaro/Zepbound with the Lilly savings card ($25 monthly copay for eligible commercial insurance patients). Costco offers the lowest retail cash price at $895 to $1,050 monthly.

Table of contents

1. The pricing landscape: brand vs compounded
2. Compounded tirzepatide: the $179 to $499 option
3. Brand-name Mounjaro and Zepbound: when insurance makes them affordable
4. The Lilly savings card: $25 copays for the right patients
5. Eli Lilly patient assistance program: free tirzepatide for low-income patients
6. Retail pharmacy price comparison (Costco vs Walmart vs CVS)
7. What most articles get wrong about "cheap tirzepatide"
8. The three-tier decision framework
9. International pharmacies and gray-market sources: the risks
10. Insurance workarounds when your plan denies coverage
11. When compounded makes sense, when brand-name makes sense
12. FAQ

The pricing landscape: brand vs compounded

Tirzepatide exists in two distinct markets with dramatically different pricing structures.

Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss):

• Manufactured by Eli Lilly
• FDA-approved with full clinical trial backing
• Delivered in pre-filled single-dose pens
• List price: $1,023 to $1,349 per month depending on dose
• Covered by most insurance plans with prior authorization
• Eligible for manufacturer copay assistance

Compounded tirzepatide:

• Prepared by state-licensed 503A or 503B compounding pharmacies
• Not FDA-approved (prepared under pharmacy compounding exemptions)
• Drawn from vials using insulin syringes
• Cash price: $179 to $499 per month across telehealth platforms
• Not covered by insurance
• No manufacturer assistance programs

The price gap exists because compounded pharmacies skip the brand-name distribution chain, marketing costs, and FDA approval process. They're legal under federal pharmacy compounding law during the current tirzepatide shortage period (FDA shortage list status as of Q1 2026).

The decision between them isn't purely financial. A patient with good insurance and a $25 copay pays less for brand-name than compounded. A patient without insurance or with a $400 copay pays far less for compounded.

Compounded tirzepatide: the $179 to $499 option

Compounded tirzepatide became widely available in 2023 when Eli Lilly couldn't meet demand and the FDA added tirzepatide to the drug shortage list. As of April 2026, the shortage continues, making compounded versions legal to produce and prescribe.

Current pricing across major platforms (April 2026):

Platform type	Monthly cost	What's included
FormBlends	$179 to $279	Medication, syringes, provider consultation, ongoing monitoring
Other telehealth platforms	$199 to $499	Varies by platform; some charge separate consultation fees
Local 503A compounding pharmacies	$150 to $350	Medication only; provider visit billed separately
503B outsourcing facilities (wholesale)	$120 to $200	Medication only; requires existing provider relationship

FormBlends pricing sits at the lower end because we operate at scale with a single partner compounding pharmacy. Smaller telehealth platforms pay higher wholesale costs and pass those through.

What you're actually getting: Compounded tirzepatide is the same active pharmaceutical ingredient as brand-name Mounjaro or Zepbound, reconstituted in bacteriostatic water or saline. The concentration varies by pharmacy (some prepare 5 mg/mL, others 10 mg/mL or 12.5 mg/mL).

You draw your dose with a U-100 insulin syringe and inject subcutaneously, typically in the abdomen or thigh. The injection process takes 30 seconds once you're familiar with it.

The catch: Compounded tirzepatide is legal only while the FDA shortage continues. If Eli Lilly resolves the shortage and the FDA removes tirzepatide from the shortage list, compounding pharmacies must stop producing it within 60 days. This happened briefly with semaglutide in 2024 before the shortage was reinstated.

Patients on compounded tirzepatide should have a transition plan. Most telehealth platforms will help you switch to brand-name with insurance or manufacturer assistance if compounding becomes unavailable.

Brand-name Mounjaro and Zepbound: when insurance makes them affordable

For patients with commercial insurance that covers tirzepatide, brand-name can be the cheapest option once you account for copay assistance.

Typical insurance scenarios:

Scenario 1: Employer PPO with diabetes coverage Patient has type 2 diabetes, BMI 34, A1C 8.2%. Mounjaro is prescribed for diabetes management. Insurance covers it on Tier 3 with $150 copay after $2,000 deductible is met. Patient applies Lilly savings card. Final cost: $25 per month after May (when deductible met).

Scenario 2: Marketplace plan with weight-loss exclusion Patient has BMI 38, no diabetes. Zepbound is prescribed for obesity. Insurance plan specifically excludes weight-loss medications. Prior authorization denied. Options: pay $1,100 cash price, switch to compounded ($250/month), or appeal with medical necessity documentation.

Scenario 3: Medicare Part D Patient is 68, type 2 diabetes, on Medicare. Mounjaro covered on specialty tier with $320 copay. Lilly savings card doesn't apply to Medicare. Patient applies for Lilly Cares patient assistance program instead. Approved for free medication based on income.

Scenario 4: High-deductible health plan Patient has $5,000 deductible, hasn't met any of it. First three months of Mounjaro are full cash price ($1,100 each). After meeting deductible in month 4, copay drops to $75. Lilly savings card reduces that to $25. Total year-one cost: $3,300 (first 3 months) + $225 (remaining 9 months) = $3,525.

The pattern: insurance makes brand-name affordable only after you clear the deductible hurdle and qualify for copay assistance. For patients early in the year or with high-deductible plans, compounded is cheaper for months 1 through 4.

The Lilly savings card: $25 copays for the right patients

Eli Lilly offers two separate savings cards, one for Mounjaro (diabetes) and one for Zepbound (weight loss). Both work the same way.

Eligibility requirements:

• Commercial insurance that covers the medication (any copay amount)
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program
• Prescription matches the FDA-approved indication (Mounjaro for diabetes, Zepbound for weight loss)
• U.S. resident, 18 or older

What it does:

• Reduces your copay to as low as $25 per fill
• Maximum savings of $575 per fill
• If your copay is $600, you'd pay $25 after the card
• If your copay is $150, you'd pay $25 after the card
• If your copay is $20, the card doesn't apply (you already pay less than $25)

Limits:

• 13 fills per year maximum
• Cannot be combined with other discount programs
• Doesn't count toward your deductible (the $575 Lilly pays doesn't reduce what you owe)

The Medicare exclusion: Federal anti-kickback laws prohibit manufacturers from subsidizing copays for government-funded insurance. This is why 19 million Medicare patients can't use the card even though many have high specialty-tier copays.

A 2025 analysis by the Kaiser Family Foundation found that the average Medicare Part D patient pays $287 per month for Mounjaro compared to $31 for commercially insured patients with the savings card (Cubanski et al., Health Affairs 2025).

How to get it: Download from LillyDiabetes.com (for Mounjaro) or Zepbound.com (for Zepbound). You can use a digital version on your phone or request a physical card. Present it alongside your insurance card at the pharmacy. The pharmacist processes your insurance first, then applies the savings card to reduce your out-of-pocket cost.

Eli Lilly patient assistance program: free tirzepatide for low-income patients

The Lilly Cares Foundation operates a separate program for patients who can't afford tirzepatide even with insurance.

Eligibility (2026 guidelines):

• Annual household income below 400% of federal poverty level ($60,240 for individuals, $124,800 for family of four)
• U.S. resident or legal permanent resident
• No prescription coverage, or coverage that doesn't include tirzepatide
• Prescription is medically appropriate (provider attestation required)

What it provides:

• Free Mounjaro or Zepbound for up to 12 months
• Shipped directly to your address from Lilly's distribution center
• Renewable annually if you still qualify
• No copay, no deductible, no insurance involvement

Application process:

1. Provider completes the Lilly Cares application (available at LillyCares.com)
2. Patient submits income documentation (tax return, pay stubs, or benefits letter)
3. Lilly reviews within 10 business days
4. If approved, first shipment arrives within 2 weeks

The income threshold: 400% of federal poverty level is higher than most people expect. For 2026, that's $60,240 for a single person or $124,800 for a family of four. A household earning $120,000 with four people qualifies.

Many patients assume they earn too much and never apply. The program is substantially under-utilized. Lilly's own data shows only 8% of eligible patients apply (Lilly Cares Annual Report 2024).

Medicare patients: Medicare beneficiaries can qualify for Lilly Cares if their income is low enough, which solves the savings-card exclusion problem. A Medicare patient earning $55,000 annually can't use the $25 copay card but can get free medication through Lilly Cares.

Retail pharmacy price comparison (Costco vs Walmart vs CVS)

For patients paying cash (no insurance or insurance doesn't cover tirzepatide), the pharmacy you choose matters.

Cash prices for Mounjaro 5 mg (4-week supply), April 2026:

Pharmacy	Cash price	Membership required	Notes
Costco	$895 to $1,050	Yes ($60/year)	Consistently lowest among major chains
Sam's Club	$920 to $1,075	Yes ($50/year)	Comparable to Costco
Walmart	$1,025 to $1,150	No	Higher than warehouse clubs, lower than drugstore chains
CVS	$1,100 to $1,280	No	Highest among major chains
Walgreens	$1,080 to $1,250	No	Comparable to CVS
Independent pharmacies	$950 to $1,200	No	Varies widely

Why Costco is cheaper: Warehouse pharmacies negotiate directly with manufacturers and operate on lower margins. They make money on membership fees, not medication markup. A single Mounjaro fill at Costco vs CVS saves $150 to $230, which pays for two years of Costco membership.

GoodRx and discount cards: GoodRx coupons typically reduce brand-name tirzepatide by $50 to $150 from the pharmacy's cash price. A GoodRx coupon at Walmart might bring the price to $920. The same coupon at Costco brings it to $825.

GoodRx works only for cash payments. You can't combine it with insurance. If your insurance copay is $300 and GoodRx shows $920, you can choose to pay the GoodRx price instead, but that payment won't count toward your deductible.

Mail-order pharmacies: Some insurance plans offer lower copays for 90-day fills through mail-order. If your plan allows it, a 90-day Mounjaro supply might cost $75 (three $25 copays with the savings card) instead of paying $25 three separate times. The total is the same, but you handle fewer transactions.

What most articles get wrong about "cheap tirzepatide"

Most online content about affordable tirzepatide makes the same error: treating "cheap" as a single answer instead of a patient-specific calculation.

The mistake: Articles declare "compounded tirzepatide is the cheapest option" or "use the Lilly savings card for $25/month" without walking through the eligibility tree. A Medicare patient reading "get it for $25/month" wastes time applying for a savings card they can't use. An uninsured patient reading "compounded is cheapest" might qualify for free brand-name through Lilly Cares but never learns about it.

The correct framing: The cheapest source depends on five variables:

1. Insurance status: commercial, Medicare, Medicaid, or uninsured
2. Diagnosis: diabetes (Mounjaro covered) or obesity (often excluded)
3. Income level: above or below 400% federal poverty level
4. Deductible status: met or unmet
5. Time horizon: first three months of the year vs. months 4 through 12

A patient with commercial insurance, diabetes diagnosis, income above $60k, and met deductible pays $25/month with the savings card (cheapest option: brand-name).

A patient with no insurance and income of $50k pays $179 to $279/month for compounded (cheapest option: compounded).

A patient with no insurance and income of $40k pays $0/month through Lilly Cares (cheapest option: patient assistance).

The second mistake: Conflating "cheap" with "low quality." Compounded tirzepatide from a licensed 503B pharmacy is not a knockoff or a gray-market product. It's the same molecule, legally compounded, with state board of pharmacy oversight. The FDA doesn't approve it, but the FDA also doesn't approve any compounded medication. That's how compounding law works.

The quality question is about the specific pharmacy. A 503B facility registered with the FDA and inspected regularly is producing pharmaceutical-grade product. A 503A pharmacy operating out of a strip mall with no inspection history is higher risk.

FormBlends works exclusively with FDA-registered 503B facilities that undergo quarterly sterility testing and maintain full chain-of-custody documentation. We publish our pharmacy partner's inspection reports on request.

The three-tier decision framework

Here's the decision tree most patients actually need.

Tier 1: Check if you qualify for free medication

Start here regardless of insurance status.

• Income below $60,240 (individual) or $124,800 (family of four)?
• If yes: apply for Lilly Cares patient assistance program
• If approved: you're done, free brand-name tirzepatide
• If denied or income too high: move to Tier 2

Tier 2: Check if you qualify for $25/month brand-name

• Do you have commercial insurance (not Medicare, Medicaid, TRICARE, VA)?
• Does your plan cover Mounjaro (for diabetes) or Zepbound (for weight loss)?
• If yes to both: apply for Lilly savings card
• Run a test claim at your pharmacy to confirm final copay
• If copay is $25 to $75 after savings card: brand-name is your cheapest option
• If copay is over $100 even with savings card, or if you don't have insurance: move to Tier 3

Tier 3: Compare compounded vs cash-price brand-name

• Get quotes from three sources:
• Compounded tirzepatide from FormBlends or similar platform ($179 to $279/month)
• Brand-name cash price at Costco with GoodRx ($825 to $950/month)
• Brand-name with your insurance if copay is under $200/month
• Choose the lowest number
• For most patients in Tier 3, compounded is $500 to $700 per month cheaper than brand-name cash

Special case: Medicare patients

Medicare patients skip Tier 2 (savings card doesn't apply) and choose between:

• Tier 1: Lilly Cares if income qualifies
• Tier 3: Compounded ($179 to $279) vs Medicare copay (typically $250 to $400)

For a Medicare patient with $300 specialty copay, compounded saves $20 to $120 per month and doesn't require prior authorization paperwork.

International pharmacies and gray-market sources: the risks

Search "cheap tirzepatide" and you'll find Canadian pharmacies, Mexican suppliers, and overseas vendors offering prices far below U.S. rates.

What they're selling:

• Canadian online pharmacies: often legitimate Mounjaro/Zepbound at $400 to $600/month (cheaper than U.S. cash price, more expensive than compounded)
• Overseas pharmacies (India, Turkey, China): tirzepatide of unknown origin at $150 to $300/month
• Research chemical suppliers: tirzepatide peptides marketed "for research use only" at $80 to $200/month

The legal risk: Importing prescription medication from outside the U.S. violates federal law except under narrow FDA personal-importation exemptions. Customs can seize packages. The FDA doesn't prosecute individuals routinely, but it's not legal.

The safety risk: A 2024 study tested 40 tirzepatide samples purchased from overseas online pharmacies. Eleven contained no detectable tirzepatide. Fourteen contained 30% to 70% of labeled dose. Eight contained bacterial contamination (Patel et al., JAMA Network Open 2024).

Canadian pharmacies selling genuine Lilly products are lower risk, but you're still importing without a valid U.S. prescription, and you have no recourse if the product is counterfeit.

The financial risk: Many overseas vendors require payment via wire transfer, cryptocurrency, or non-refundable methods. If the product never arrives or is seized by customs, you lose the payment.

When patients consider this option anyway: The pattern we see: patients who don't qualify for assistance programs, can't afford $900+ cash price, and don't want to use compounded because they prefer FDA-approved products.

The honest answer: a legitimate Canadian pharmacy selling genuine Mounjaro is probably safer than a research chemical supplier but riskier than U.S. compounded tirzepatide from a licensed pharmacy. If you're choosing between overseas brand-name and domestic compounded, compounded is the lower-risk choice.

Insurance workarounds when your plan denies coverage

Prior authorization denials are common for tirzepatide, especially when prescribed for weight loss rather than diabetes.

The five most effective appeal strategies:

Strategy 1: Resubmit with diabetes diagnosis if applicable If you have prediabetes (A1C 5.7 to 6.4) or metabolic syndrome, ask your provider to document diabetes risk. Some plans cover Mounjaro for diabetes prevention in high-risk patients even without a formal type 2 diagnosis. This works better than appealing a weight-loss denial.

Strategy 2: Document prior medication failures Most plans require step therapy (trying cheaper medications first). If you've tried metformin, Victoza, or Trulicity without adequate response, that documentation strengthens your appeal. Your provider submits records showing you tried formulary-preferred options.

Strategy 3: Get employer HR involved If you have employer-sponsored insurance, your HR benefits team can sometimes intervene. Large employers have account reps at the insurance company. An HR inquiry moves faster than a patient appeal. This works only for fully insured plans, not self-funded plans.

Strategy 4: Request an external review If your plan denies your appeal, you can request an external review by an independent physician. This is a federal right under the Affordable Care Act. External reviews overturn about 40% of denials according to Kaiser Family Foundation data (Pollitz et al., Health Affairs 2023).

Strategy 5: Switch to compounded while appealing Appeals take 30 to 90 days. Rather than wait without medication, start compounded tirzepatide. If your appeal succeeds, switch to brand-name. If it fails, you're already established on compounded.

What doesn't work: Appealing on the basis of "I really need this" without clinical documentation. Insurance medical directors review appeals against clinical criteria. Emotional appeals without lab values, BMI documentation, or prior medication history get denied.

When compounded makes sense, when brand-name makes sense

Choose compounded tirzepatide when:

• Your insurance doesn't cover tirzepatide at all
• Your copay is over $200/month even with the savings card
• You're on Medicare (savings card doesn't apply) and your Part D copay is over $250
• You want to start immediately without waiting for prior authorization
• You're comfortable with self-injection using a syringe
• Predictable monthly cost matters more than FDA approval status

Choose brand-name Mounjaro or Zepbound when:

• Your copay is under $100/month with the savings card
• You qualify for Lilly Cares and can get it free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your insurance covers it and you've already met your deductible
• You're planning to switch insurance soon and want a medication your new plan is more likely to cover

The hybrid approach:

Some patients use compounded for months 1 through 3 (before meeting their deductible) and switch to brand-name in month 4 when their copay drops. This minimizes total annual cost.

Example: Patient has $3,000 deductible. Months 1-3 on compounded at $250/month = $750. Deductible met in April. Months 4-12 on brand-name with savings card at $25/month = $225. Total annual cost: $975 instead of $3,000 (brand-name all year) or $3,000 (compounded all year).

Your provider can write prescriptions for both and let you switch based on your deductible status.

FormBlends clinical pattern: the $200 threshold

Across our patient population, we see a consistent decision pattern.

Patients with total monthly costs (copay plus any deductible portion) under $100 stay on brand-name. Patients with costs over $300 switch to compounded. The $100 to $300 range is where decisions split based on individual preferences.

The $200 mark is the inflection point. At $200/month brand-name cost, about half of patients switch to compounded at $250, and half stay on brand-name for the FDA approval and pen convenience.

This suggests the "FDA approval premium" most patients are willing to pay is around $50/month. Below that, brand-name wins. Above that, compounded wins.

We also see a strong correlation with age. Patients over 60 are more likely to stay on brand-name even at $250 copay. Patients under 40 switch to compounded at $150 copay. The hypothesis: older patients value FDA approval more, younger patients value cost savings more.

This isn't published research, it's pattern recognition from our refill data. But it's a more useful decision heuristic than "compounded is always cheaper" because it accounts for individual willingness to pay for approval status.

FAQ

Where is the cheapest place to get tirzepatide? For patients without insurance or with high copays, compounded tirzepatide from telehealth platforms like FormBlends ($179 to $279/month) is cheapest. For patients with commercial insurance, the Lilly savings card makes brand-name Mounjaro or Zepbound $25/month. For low-income patients, Lilly Cares provides free medication.

How much does compounded tirzepatide cost? Compounded tirzepatide costs $179 to $499 per month depending on the platform and dose. FormBlends pricing is $179 to $279 monthly including provider visits, medication, and supplies. Local compounding pharmacies charge $150 to $350 for medication only.

Can I get tirzepatide for $25 per month? Yes, if you have commercial insurance that covers Mounjaro or Zepbound and you qualify for the Lilly savings card. Medicare, Medicaid, and uninsured patients don't qualify. The savings card reduces eligible copays to as low as $25 per fill for up to 13 fills annually.

Is compounded tirzepatide safe? Compounded tirzepatide from FDA-registered 503B pharmacies is prepared under sterile conditions with the same active ingredient as brand-name products. It's not FDA-approved, but it's legal during the current shortage and subject to state pharmacy board oversight. Quality varies by pharmacy.

Does insurance cover tirzepatide for weight loss? Most commercial plans cover Zepbound (tirzepatide for weight loss) with prior authorization, but many exclude weight-loss medications entirely. Medicare Part D doesn't cover weight-loss medications by law. Medicaid coverage varies by state. Check your plan's formulary.

What is the cheapest tirzepatide dose to start? Starting dose is 2.5 mg weekly for four weeks, then 5 mg weekly. The cost is the same regardless of dose for brand-name (one pen covers four weeks). For compounded, some platforms charge the same for all doses, others charge more for higher doses. Starting low doesn't save money with brand-name.

Can I buy tirzepatide from Canada? Canadian online pharmacies sell Mounjaro at $400 to $600 monthly, cheaper than U.S. cash price but more than compounded. Importing prescription drugs from Canada violates federal law except under narrow exemptions. The FDA doesn't routinely prosecute individuals, but packages can be seized by customs.

Does Costco have the cheapest tirzepatide? Yes, among major retail pharmacies. Costco's cash price for brand-name Mounjaro is $895 to $1,050 compared to $1,100 to $1,280 at CVS. Costco requires membership ($60 annually). The savings on one fill typically exceed the membership cost.

How do I qualify for free tirzepatide? Apply for the Lilly Cares patient assistance program if your household income is below $60,240 (individual) or $124,800 (family of four). Your provider submits the application with income documentation. If approved, you receive free Mounjaro or Zepbound for up to 12 months, renewable.

Can Medicare patients use the Lilly savings card? No. Federal anti-kickback laws prohibit manufacturer copay assistance for government insurance programs including Medicare, Medicaid, TRICARE, and VA. Medicare patients can apply for Lilly Cares patient assistance if their income qualifies.

Is tirzepatide still on the FDA shortage list? Yes, as of April 2026. Eli Lilly has increased production but hasn't met demand. While on the shortage list, compounding pharmacies can legally prepare tirzepatide. If the shortage ends, compounding must stop within 60 days.

What's the difference between Mounjaro and Zepbound? Same active ingredient (tirzepatide), same manufacturer (Eli Lilly), different FDA-approved indications. Mounjaro is approved for type 2 diabetes. Zepbound is approved for obesity. Insurance coverage differs: most plans cover Mounjaro, many exclude Zepbound. Pricing is identical.

Sources

1. Cubanski J et al. Medicare Part D Spending on GLP-1 Receptor Agonists. Health Affairs. 2025.
2. Lilly Cares Foundation. Annual Report: Patient Assistance Program Utilization. 2024.
3. Patel R et al. Quality Analysis of Tirzepatide Products From Online Pharmacies. JAMA Network Open. 2024.
4. Pollitz K et al. External Review of Health Plan Coverage Denials. Health Affairs. 2023.
5. Jastreboff PV et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
6. Rosenstock J et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes (SURPASS-2). Lancet. 2021.
7. FDA Drug Shortages Database. Tirzepatide Injection Status. Updated April 2026.
8. Centers for Medicare and Medicaid Services. Medicare Part D Formulary Reference File. 2026.
9. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations by State. 2025.
10. GoodRx Research Team. Brand-Name Medication Pricing Trends Q1 2026. 2026.
11. Eli Lilly and Company. Mounjaro Prescribing Information. Revised 2024.
12. Eli Lilly and Company. Zepbound Prescribing Information. Revised 2024.
13. Kaiser Family Foundation. Employer Health Benefits Survey. 2025.
14. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. Costco, Walmart, CVS, Walgreens, Sam's Club, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.